Results

Total Results: 2,209 records

Showing results for "drug".

1981. Long COVID Models of Care | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/long-covid-models-care/protocol
      June 15, 2023 - Skip to main content An official website of the Department of Health & Human Services Careers Contact Us Español FAQs Effective Health Care Program Powered by the Evidence-based Practice Centers …

1982. Long COVID Models of Care (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/long-covid-protocol.pdf
      February 18, 2023 - Long COVID Models of Care Evidence-based Practice Center Technical Brief Protocol Project Title: Long COVID Models of Care I. Background and Objectives for the Technical Brief A large, growing population of persons have experienced severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectio…

1983. Geographic Variation in Carotid Endarterectomy and Carotid Stenting Among Medicare Beneficiaries, 2003-2006 (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/cardiology-health-outcomes_research.pdf
      July 01, 2010 - Medicare & Medicaid Services (CMS) issued a national coverage decision supporting the use of Food and Drug

1984. App-D-Surv-Report-2-Noninvasive-Nonpharma (xls file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/app-d-surv-report-2-noninvasive-nonpharma.xlsx
      January 01, 2021 - communication and cognitive problems, acute inflammation at the application site, knee joint surgery or drug … blind; pregnant, lactating, or that they anticipate becoming pregnant in the next 3 months; current drug

1985. App-D-Surv-Report-1-Noninvasive-Nonpharma 0 (xls file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/app-d-surv-report-1-noninvasive-nonpharma_0.xlsx
      January 01, 2021 - communication and cognitive problems, acute inflammation at the application site, knee joint surgery or drug … blind; pregnant, lactating, or that they anticipate becoming pregnant in the next 3 months; current drug

1986. Future Research Needs for Attention Deficit Hyperactivity Disorder: Effectiveness of Treatment in At-Risk Preschoolers, Long-Term Effectiveness in All Ages, and Variability in Prevalence, Diagnosis, and Treatment (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/adhd-future_research.pdf
      May 01, 2012 - As part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Congress directed … Food and Drug Administration Division of Psychiatry Products Silver Spring, MD Stephen Faraone, … Such secondary data, however, may not be optimal for examination of drug benefits, which generally requires

1987. VTE Surveillance Assessment_49_low_SPI (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/blood-clots-hip-knee-surgery_surveillance.pdf
      December 01, 2012 - The Food and Drug Administration (FDA), Health Canada, and Medicines and Healthcare products Regulatory … would produce prima facie evidence that a conclusion was out of date, such as the withdrawal of a drug … Uptodate CER=comparative effectiveness review; FDA=food and drug administration; NA=not applicable;

1988. Nppv-Respiratory-Failure Executive (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/nppv-respiratory-failure_executive.pdf
      July 01, 2012 - Food and Drug Administration for any unpublished RCT data available for devices used to provide noninvasive … Food and Drug Administration; ICU = intensive care unit; KQ = Key Question; NPPV = noninvasive positive-pressure

1989. Comparative Effectiveness of Strategies to De-escalate Aggressive Behavior in Psychiatric Patients in Acute Care Settings (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/aggression_executive.pdf
      October 01, 2016 - One RCT43 examined three possible harms: drug-related adverse effects; incidence of abnormal QT (QRS … flunitrazepam, no statistical testing reported (3 vs. 3, p=NR).48 Drug-related adverse events 91

1990. Genetic Testing for Developmental and Intellectual Disabilities | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/genetic-testing-developmental-disabilities/research-protocol
      September 30, 2014 - Food and Drug Administration (FDA) or as a laboratory-developed test (LDT). 20,21 FDA-cleared or -approved … Food and Drug Administration; LDT—laboratory-developed test Test Describe the full name of

1991. new disposition of comments insulin analogues -- jda revs.xls (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/insulin-analogues-disposition-081229.pdf
      September 01, 2008 - new disposition of comments insulin analogues -- jda revs.xls                                                                                                                                                Comment, by Section Response Executive Summary Comment: A statement under Gaps in Evidence and Future Direction…

1992. Disposition of Comments for Strategies To Prevent Weight Gain Among Adults (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/weight-gain-prevention_disposition-comments.pdf
      March 25, 2013 - We agree that a future research need is identifying the best tool to assess quality for non-drug/device

1993. Pressure-Ulcer-Treatment Executive (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/pressure-ulcer-treatment_executive.pdf
      May 01, 2013 - Scientific information packets (SIPs) were requested from identified drug and device manufacturers,

1994. Disposition of Comments for CER 196 The Role of Immunotherapy in the Treatment of Asthma (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-196-disposition-comments-immunotherapy-asthma.pdf
      March 23, 2018 - Drug Saf 2005; 28:1057-63) As you note, this information is not usually available in the manuscripts

1995. Gout Executive-2016 (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/gout_executive-2016.pdf
      January 01, 2016 - Drug expenditures accounted for 61 percent of the total costs.2 In addition to gout, the types of … development of inflammation and pain, erythema, monoarthritis, response to administration of the drug

1996. Disposition of Comments Report for Assessment and Management of Chronic Cough (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/chronic-cough_disposition-comments.pdf
      January 07, 2013 - Disposition of Comments Report for Assessment and Management of Chronic Cough Source: http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and- reports/?pageaction=displayproduct&productID=1371 Published Online: January 7, 2013 Comparative Effectiveness Research Review Disposition of Comments Repor…

1997. Inguinal-Hernia Executive (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/inguinal-hernia_executive.pdf
      August 01, 2012 - Food and Drug Administration, input from the Technical Expert Panel, and the consensus of the research

1998. Evidence-based Practice Center Systematic Review Protocol (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/procalcitonin_research-protocol.pdf
      September 08, 2011 - Information Packets from the Scientific Resource Center and gray literature from conferences, the Food and Drug

1999. Comparative Effectiveness of Non-Invasive Diagnostic Tests for Breast Abnormalities – An Update of a 2006 Report | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/breast-abnormalities-tests-update/research-protocol
      June 28, 2010 - Food and Drug Administration for use as a diagnostic test for breast cancer, and are defined as stand-alone

2000. Methods Guide for Medical Test Reviews Chapter 12 (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/methods-guidance-tests-prognostic_methods.pdf
      July 01, 2012 - If a prognostic test has been submitted for review by regulatory agencies such as the Food and Drug